AZD treatment did not improve obesity (body weight, Figure 4a, b), hyperglycaemia (Figure 4c, Supplementary Figure 4), hyperinsulinemia (Figure 4d) or insulin resistance (adiponectin, Supplementary Figure 4). Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.